TFF Pharmaceuticals, Inc.
TFFP · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | $0 |
| % Margin | 31.5% | – | – | – |
| R&D Expenses | $12 | $18 | $21 | $11 |
| G&A Expenses | $11 | $14 | $11 | $8 |
| SG&A Expenses | $11 | $14 | $11 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$0 | $0 |
| Operating Expenses | $22 | $32 | $32 | $19 |
| Operating Income | -$22 | -$32 | -$32 | -$19 |
| % Margin | -2,983.4% | – | – | – |
| Other Income/Exp. Net | $1 | $0 | $1 | $0 |
| Pre-Tax Income | -$21 | -$32 | -$31 | -$19 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$21 | -$32 | -$31 | -$18 |
| % Margin | -2,894.7% | – | – | – |
| EPS | -11.85 | -26.49 | -31.21 | -22.57 |
| % Growth | 55.3% | 15.1% | -38.3% | – |
| EPS Diluted | -11.85 | -26.49 | -31.21 | -22.57 |
| Weighted Avg Shares Out | 2 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 2 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $0 | $0 | $0 |
| EBITDA | -$21 | -$31 | -$31 | -$19 |
| % Margin | -2,826.2% | – | – | – |